Recording from the STAT co-working space outside the J.P. Morgan Healthcare Conference, we discuss how a spate of deals and some intermittent sunshine seem to have brightened the outlook for biotech at the outset of 2024. We also talk about the latest twist in the Sarepta Therapeutics saga, a ubiquitous dealmaker, and life on the party circuit. For more on what we cover, here's the news on Sarepta; here's more on Nvidia; here's the story on Centerview; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here's where you can subscribe to our biotech newsletter, The Readout.